8-K: Viking Therapeutics Announces Year-End 2023 Financial Results and Provides Clinical Pipeline Update

Viking Therapeutics reported its fourth quarter and full-year 2023 financial results, highlighted by a strong cash position of $362 million and progress across its clinical programs.

Summary

• Viking Therapeutics announced its financial results for the fourth quarter and year ended December 31, 2023, along with updates on its clinical pipeline.
• The company reported a net loss of $24.6 million for the fourth quarter of 2023, or $0.25 per share, compared to a net loss of $19.6 million, or $0.26 per share, for the same period in 2022.
• For the full year 2023, Viking reported a net loss of $85.9 million, or $0.91 per share, compared to a net loss of $68.9 million, or $0.90 per share, in 2022.
• Research and development expenses increased to $20.5 million in Q4 2023 and $63.8 million for the full year, driven by increased clinical and pre-clinical study costs.
• General and administrative expenses also increased to $8.8 million in Q4 2023 and $37.0 million for the full year, primarily due to increased legal and patent service costs.
• The company ended the year with a strong cash position of $362 million, which will support its objectives for 2024 and beyond.
• Topline results from the Phase 2 VENTURE trial of VK2735 for obesity and the Phase 1 trial of oral VK2735 are expected in the first quarter of 2024.
• Histology results from the Phase 2b VOYAGE study of VK2809 for NASH and fibrosis are expected in the first half of 2024.
• Results from the Phase 1b study of VK0214 for X-ALD are also expected in the first half of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong clinical progress and a solid cash position, but the increased losses and lack of revenue temper the overall sentiment.

Positives

• Viking has a strong cash position of $362 million, providing financial stability for ongoing and future clinical trials.
• The company has multiple clinical programs advancing with key data readouts expected in the near term.
• VK2735 has shown promising early efficacy and safety signals in Phase 1 trials, including significant reductions in body weight and liver fat.
• VK2809 has demonstrated statistically significant reductions in liver fat and improvements in lipid profiles in the VOYAGE study.
• The company is exploring both subcutaneous and oral formulations of VK2735, potentially expanding its market opportunity.
• Viking's clinical programs are targeting significant unmet medical needs in metabolic and endocrine disorders.

Negatives

• The company reported increased net losses for both the fourth quarter and full year 2023 compared to 2022.
• Research and development expenses and general and administrative expenses have increased significantly year-over-year.
• The company is still in the clinical stage and has not yet generated revenue from product sales.

Risks

• Clinical trial results may not be as positive as expected, potentially delaying or halting development programs.
• Regulatory approvals for the company's drug candidates are not guaranteed.
• The company may need to raise additional capital in the future to fund its operations.
• Competition in the metabolic and endocrine disorder space is intense.
• The company's reliance on third-party manufacturers and suppliers could pose risks to its supply chain.

Future Outlook

The company anticipates reporting topline results from multiple clinical trials in the first half of 2024, including the Phase 2 VENTURE trial of VK2735, the Phase 1 trial of oral VK2735, the Phase 2b VOYAGE study of VK2809, and the Phase 1b study of VK0214. The company's strong cash position is expected to support its objectives for 2024 and beyond.

Management Comments

• 2023 was an event-filled year for Viking, with the company achieving significant progress with each of our four clinical programs, stated Brian Lian, Ph.D., chief executive officer of Viking.
• We look forward to an exciting year ahead and thank our shareholders and partners, as well as the investigators and patients participating in our clinical programs, for their continued support.

Industry Context

Viking's focus on developing novel therapies for metabolic and endocrine disorders aligns with the growing global interest in addressing conditions like obesity, NASH, and rare diseases. The company's dual agonist approach with VK2735 and the liver-selective thyroid hormone receptor beta agonist approach with VK2809 are innovative strategies in these competitive fields.

Comparison to Industry Standards

• Viking's VK2735 is competing with other GLP-1/GIP agonists in development for obesity and diabetes, such as Eli Lilly's Tirzepatide (Mounjaro) which has shown significant weight loss and glycemic control.
• The liver fat reduction results of VK2809 in the VOYAGE study are comparable to or better than some other NASH therapies in development, such as Madrigal Pharmaceuticals' Resmetirom, which has also shown significant liver fat reduction and fibrosis improvement.
• Viking's approach to X-ALD with VK0214 is unique as there are currently no approved pharmacologic treatments for this rare neurodegenerative disease, setting it apart from other companies in the space.

Stakeholder Impact

• Shareholders will be interested in the upcoming clinical trial results and the company's financial performance.
• Employees will be impacted by the company's continued growth and development.
• Patients with metabolic and endocrine disorders may benefit from the company's novel therapies.
• Creditors will be interested in the company's financial stability and ability to repay debts.

Next Steps

• The company will report topline results from the Phase 2 VENTURE trial of VK2735 in 1Q24.
• The company will report topline results from the Phase 1 trial of oral VK2735 in 1Q24.
• The company will report histology results from the Phase 2b VOYAGE study of VK2809 in 1H24.
• The company will report results from the Phase 1b study of VK0214 in 1H24.

Key Dates

Keywords

Viking Therapeutics, VK2735, VK2809, VK0214, Obesity, NASH, X-ALD, GLP-1, GIP, Thyroid Hormone Receptor Beta Agonist, Clinical Trials, Metabolic Disorders, Endocrine Disorders, Liver Fat Reduction, Lipid Lowering